European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

PANcreatic CAncer Initial Detection via liquid biopsy

Descrizione del progetto

DE EN ES FR IT PL

Un esame del sangue per la diagnosi del tumore del pancreas

I tumori rilasciano piccole quantità di cellule o materiale cellulare nella circolazione sanguigna, che sono la base del potenziale diagnostico delle biopsie liquide le quali, tuttavia, spesso hanno sensibilità o specificità ridotte. Il progetto PANCAID, finanziato dall’UE, si concentra sullo sviluppo di un esame diagnostico per il tumore del pancreas, una delle principali cause di morte dovuta al cancro in tutto il mondo. L’esame combinerà più biomarcatori e l’intelligenza artificiale per un’analisi di elevata precisione e sensibilità. Data la prognosi infausta del tumore del pancreas, il test sviluppato da PANCAID dovrebbe agevolare la diagnosi precoce per una gestione e risultati clinici migliori.

Obiettivo

Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will therefore develop a blood test for early detection of PDAC. Despite tremendous technological advances in Liquid Biopsy Diagnostics (LBx), this goal is very ambitious because small tumors release only minute amounts of cells or cellular products (e.g. DNA, RNA, protein, metabolites) into the circulation. Thus, tests with a high sensitivity are required but increases in sensitivity are usually achieved on the expenses of reduced specificity which can lead to significant overdiagnosis leading to unnecessary stress for the individuals with a false-positive blood test and high costs for the health system. In PANCAID, we will therefore establish a blood test with high accuracy by analyzing large cohorts of patients with PDAC and its precursor lesions, individuals at risk to develop PDAC and appropriate age-matched control groups (healthy and non-cancer diseases frequent in the targeted population).
Ambitious objectives of PANCAID include (1) establishment of a unique resource of blood samples of early PDAC and risk groups (WP1); (2) Establishment of a breakthrough blood test for early diagnosis of PDAC (WP2); (3) Identification of the best composite biomarker panel by integrating multimodal features in an AI-assisted computational analysis; (4) Analysis of the socio-economic impact of early PDAC diagnosis (WP4); and (5) Definition of the ethics parameters relevant to early PDAC detection (WP5). A robust multi-biomarker panel will be determined during the training period (year 1-3) and subsequently validated on bio-banked blood samples (year 4-5). Depending on the outcome of this comprehensive analysis, PANCAID will provide the design of a future prospective study for validation of the developed composite blood test in an international multi-center setting required to introduce LBx into screening programs for high-risk individuals. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

HORIZON-MISS-2021-CANCER-02

Vedi altri progetti per questo bando

Meccanismo di finanziamento

HORIZON-RIA - HORIZON Research and Innovation Actions

Coordinatore

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Contribution nette de l'UE
€ 2 114 223,75
Indirizzo
Martinistrasse 52
20251 Hamburg
Germania

Mostra sulla mappa
Regione
Hamburg Hamburg Hamburg
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 2 114 223,75

Partecipanti (18)

Partner (1)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 30 Dicembre 2022

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/101096309/it

European Union, 2024